From October 23 to 24, CCTI 2025 China Clinical Trial Industry Development Conference was successfully held in Nanjing. Ms. Yuan Shaoxiong, Deputy General Manager of Clinical Division and Medical Business Director of Leadingpharm, was invited to deliver a themed speech titled "Clinical Trial Implementation Strategies Under the New Situation". With her accurate analysis of industry pain points and practical suggestions, the speech attracted many participants to stop and listen, resulting in a warm on-site response!
 

▲ On-site of CCTI 2025 China Clinical Trial Industry Development Conference

At present, clinical research is facing the dual challenges of "low-level repetition of targets + clinical trial involution". The development of new targets and international linkage are the key to breaking the deadlock. Ms. Yuan focused her speech on three core aspects:

1. Analyzing the current new situation of domestic clinical trial implementation and exploring ways to leverage opportunities and break through difficulties;
2. Introducing the development of the special track of CGT (Cell and Gene Therapy), mentioning that global CGT clinical trials are mainly based on cell therapy, with indications expanding to non-oncological fields, and sharing the R&D progress of related drugs at home and abroad;
3. Presenting typical cases and practical suggestions. Based on the successful projects of Leadingpharm CXO · Zhengzhou Deep Blue Ocean Biopharmaceutical Technology Co., Ltd in the field of clinical research, she explained the clinical transformation logic in detail with application cases of CAR-T and monoclonal antibody/bispecific antibody, and suggested that enterprises could accelerate trials by virtue of pilot city policies and intelligent tools.

▲ Ms. Yuan Shaoxiong delivering the themed speech
 

In addition to the themed speech, Ms. Yuan Shaoxiong was also invited to serve as a guest at the roundtable forum. Centering on the core topic of "Future Trends in the Development of the Clinical Trial Industry", she conducted in-depth discussions with experts from pharmaceutical companies, CRO institutions and industry organizations, providing ideas for the coordinated development of the industry.
 

▲ Awarded the "2025 Outstanding Clinical Research Supplier" Award

This conference attracted more than 1,000 clinical research professionals to conduct in-depth on-site exchanges and discuss cooperation, jointly exploring the current situation and future of the clinical trial industry. Leadingpharm CXO · Zhengzhou Deep Blue Ocean Biopharmaceutical Technology Co., Ltd gathered experts from various fields such as medicine and business, and conducted in-depth communication and discussions with colleagues from all walks of life in the field of innovative drug clinical research. The on-site response was enthusiastic, and all parties expressed their willingness to work together to promote the high-quality development of China's innovative drug clinical research.

▲ On-site of the booth

As a full-process partner in new drug development, Leadingpharm has always adhered to the cooperative concept of innovation and win-win, committed to optimizing the new drug R&D process and improving R&D efficiency and quality. In the future, Leadingpharm will continue to deepen its efforts in the fields of cell therapy and new drug development, contributing more to promoting the development of China's innovative drug clinical research.

About Us

Zhengzhou Deep Blue Ocean Biopharmaceutical Technology Co., Ltd is a sub-brand of Leadingpharm (Stock Code: 600222) in the clinical CRO field. Founded in 2007, it adheres to the service concept of "Taking the end as the beginning, top-level design, and being a full-process partner in new drug development". It provides global pharmaceutical companies with services covering Phase I-III clinical research, bioequivalence research, post-marketing research, third-party auditing, IND and NDA declarations, and medical affairs for biopharmaceuticals, chemical drugs, traditional Chinese medicines, medical devices, and cell and gene therapy. It can meet the customized clinical research needs of different R&D-oriented enterprises and help domestic and foreign customers break through the key bottlenecks before new drug listing.

At present, the company has carried out more than 2,000 clinical research projects, including dozens of Class I innovative drug projects and 50-100 BE research projects every year. In addition to conducting business in the fields of rheumatology and immunology, oncology, cardiovascular and cerebrovascular diseases, and endocrinology, it has taken the lead in providing clinical research services in the fields of medical aesthetics, medical food, and cell and gene therapy drugs, filling a number of gaps at home and abroad.

-END-